Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 29047 | 158 | 24.6 | 65% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 1971 | 5134 | O ANTIGEN//BACTERIAL POLYSACCHARIDE STRUCTURE//O SPECIFIC POLYSACCHARIDE |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | IP PA1 | Author keyword | 21 | 90% | 6% | 9 |
| 2 | INTEGRATED HOLIST IMMUNOL | Address | 9 | 50% | 8% | 13 |
| 3 | BIOTECHNOL MIYAMAE KU | Address | 8 | 100% | 3% | 5 |
| 4 | CONTROL INNATE IMMUN | Address | 6 | 80% | 3% | 4 |
| 5 | BIOTECHNOL NOGAWA MIYAMAE KU | Address | 6 | 100% | 3% | 4 |
| 6 | MACROPHAGE NETWORK | Author keyword | 3 | 100% | 2% | 3 |
| 7 | ORAL ADMINISTRATION OF LPS | Author keyword | 2 | 67% | 1% | 2 |
| 8 | ENDOGENOUS TUMOR NECROSIS FACTOR | Author keyword | 1 | 38% | 2% | 3 |
| 9 | HEAT KILLED ENTEROCOCCUS FAECALIS | Author keyword | 1 | 100% | 1% | 2 |
| 10 | LPSW | Author keyword | 1 | 100% | 1% | 2 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | IP PA1 | 21 | 90% | 6% | 9 | Search IP+PA1 | Search IP+PA1 |
| 2 | MACROPHAGE NETWORK | 3 | 100% | 2% | 3 | Search MACROPHAGE+NETWORK | Search MACROPHAGE+NETWORK |
| 3 | ORAL ADMINISTRATION OF LPS | 2 | 67% | 1% | 2 | Search ORAL+ADMINISTRATION+OF+LPS | Search ORAL+ADMINISTRATION+OF+LPS |
| 4 | ENDOGENOUS TUMOR NECROSIS FACTOR | 1 | 38% | 2% | 3 | Search ENDOGENOUS+TUMOR+NECROSIS+FACTOR | Search ENDOGENOUS+TUMOR+NECROSIS+FACTOR |
| 5 | HEAT KILLED ENTEROCOCCUS FAECALIS | 1 | 100% | 1% | 2 | Search HEAT+KILLED+ENTEROCOCCUS+FAECALIS | Search HEAT+KILLED+ENTEROCOCCUS+FAECALIS |
| 6 | LPSW | 1 | 100% | 1% | 2 | Search LPSW | Search LPSW |
| 7 | EET THERAPY | 1 | 50% | 1% | 1 | Search EET+THERAPY | Search EET+THERAPY |
| 8 | EGGSHELL BREAKING STRENGTH | 1 | 50% | 1% | 1 | Search EGGSHELL+BREAKING+STRENGTH | Search EGGSHELL+BREAKING+STRENGTH |
| 9 | FK 23 | 1 | 50% | 1% | 1 | Search FK+23 | Search FK+23 |
| 10 | HSRG1 | 1 | 50% | 1% | 1 | Search HSRG1 | Search HSRG1 |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | ACTIVATED MACROPHAGE | 9 | 39% | 11% | 18 |
| 2 | LPSW | 6 | 80% | 3% | 4 |
| 3 | MACROPHAGE NETWORK THEORY | 6 | 100% | 3% | 4 |
| 4 | PANTOEA AGGLOMERANS IP PA1 | 2 | 67% | 1% | 2 |
| 5 | EET THERAPY | 1 | 50% | 1% | 2 |
| 6 | FAECALIS FK 23 | 1 | 100% | 1% | 2 |
| 7 | IP PA1 | 1 | 50% | 1% | 2 |
| 8 | PANTOEA AGGLOMERANS 1 | 1 | 100% | 1% | 2 |
| 9 | RTNF | 1 | 100% | 1% | 2 |
| 10 | FAECALIS FK 23 PREPARATION | 1 | 50% | 1% | 1 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Applications of lipopolysaccharide derived from Pantoea agglomerans (IP-PA1) for health care based on macrophage network theory | 2006 | 17 | 47 | 26% |
| Usefulness of Oral Administration of Lipopolysaccharide for Disease Prevention Through the Induction of Priming in Macrophages | 2014 | 0 | 29 | 52% |
| Transgenerational epigenetic effects on innate immunity in broilers: An underestimated field to be explored? | 2013 | 4 | 100 | 1% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | INTEGRATED HOLIST IMMUNOL | 9 | 50% | 8.2% | 13 |
| 2 | BIOTECHNOL MIYAMAE KU | 8 | 100% | 3.2% | 5 |
| 3 | CONTROL INNATE IMMUN | 6 | 80% | 2.5% | 4 |
| 4 | BIOTECHNOL NOGAWA MIYAMAE KU | 6 | 100% | 2.5% | 4 |
| 5 | PL AQUABIOL | 1 | 11% | 7.6% | 12 |
| 6 | GLOBAL ANIM OURCE SCI | 0 | 10% | 2.5% | 4 |
| 7 | PL AQUA BIOL | 0 | 33% | 0.6% | 1 |
| 8 | UNITED UATED VET SCI | 0 | 25% | 0.6% | 1 |
| 9 | MED MINATO KU | 0 | 13% | 0.6% | 1 |
| 10 | NONPROFIT ORG | 0 | 13% | 0.6% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000180889 | TOXICOL S 216 KASHIMA YODOGAWA KU//N CWS//ZAJDELA HEPATOMA |
| 2 | 0.0000135370 | MORRIS HEPATOMA 5123//TNF RECEPTORS//ENDOGENOUS TNF ALPHA |
| 3 | 0.0000111667 | LIPID A ANALOG//LIPID A//LPS ANTAGONIST |
| 4 | 0.0000098730 | B10 MOUSE//LIGHT DARKNESS TEST//INSERMU461 |
| 5 | 0.0000093955 | IMMUNOPHARMACOL MICROBIAL PROD//BETA GLUCAN//DECTIN 1 |
| 6 | 0.0000090575 | OK 432//OK432//PROD LIFECYCLE MED INFORMAT |
| 7 | 0.0000076213 | PATHOPHYSIOL THER EUT//MOL NEUROBIOL CELL BIOL UNIT//PGIBMS |
| 8 | 0.0000065680 | CALORIMETRIC REACTOR//FISCHER TROPSCH FT//EXPERT SUSTAINABLE BUSINESS OPERAT |
| 9 | 0.0000061148 | SCOTTISH FISH IMMUNOL//LIPOPOLYSACCHARIDE INDUCED TNF ALPHA FACTOR//LITAF |
| 10 | 0.0000056224 | BIOL GENET BACTERIAL CELL WALL//FC GAMMA RIII ALPHA//HUMAN INJECTIONS |